These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

322 related articles for article (PubMed ID: 33390183)

  • 21. Insights into the Immunopathophysiology of Severe COVID-19 in Metabolic Disorders.
    Shekhar S; Copacino CE; Barrera FJ; Hall JE; Hannah-Shmouni F
    Ann Natl Acad Med Sci; 2020 Apr; 56(2):112-115. PubMed ID: 33082620
    [TBL] [Abstract][Full Text] [Related]  

  • 22. COVID-19 Severity and Cardiovascular Disease: An Inseparable Link.
    Henein MY; Cameli M; Pastore MC; Mandoli GE
    J Clin Med; 2022 Jan; 11(3):. PubMed ID: 35159931
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Normal weight obesity and COVID-19 severity: A poorly recognized link.
    Sathish T; Kapoor N
    Diabetes Res Clin Pract; 2020 Nov; 169():108521. PubMed ID: 33096190
    [No Abstract]   [Full Text] [Related]  

  • 24. More Severe Obesity Leads to More Severe COVID-19 in Study.
    Kuehn BM
    JAMA; 2021 Apr; 325(16):1603. PubMed ID: 33904860
    [No Abstract]   [Full Text] [Related]  

  • 25. Covid-19: high rates of severity and death in elderly and patients with chronic diseases reinforces the importance of regular physical activity.
    Speretta GF; Leite RD
    Sport Sci Health; 2020; 16(3):589-590. PubMed ID: 32837567
    [No Abstract]   [Full Text] [Related]  

  • 26. Global pandemics interconnected - obesity, impaired metabolic health and COVID-19.
    Stefan N; Birkenfeld AL; Schulze MB
    Nat Rev Endocrinol; 2021 Mar; 17(3):135-149. PubMed ID: 33479538
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Obesity in COVID-19 era, implications for mechanisms, comorbidities, and prognosis: a review and meta-analysis.
    Aghili SMM; Ebrahimpur M; Arjmand B; Shadman Z; Pejman Sani M; Qorbani M; Larijani B; Payab M
    Int J Obes (Lond); 2021 May; 45(5):998-1016. PubMed ID: 33637951
    [TBL] [Abstract][Full Text] [Related]  

  • 28. SARS-CoV-2 and Obesity: "CoVesity"-a Pandemic Within a Pandemic.
    Zakka K; Chidambaram S; Mansour S; Mahawar K; Salminen P; Almino R; Schauer P; Kinross J; Purkayastha S;
    Obes Surg; 2021 Apr; 31(4):1745-1754. PubMed ID: 33479921
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Obesity in COVID-19: A Systematic Review and Meta-analysis.
    Ho JSY; Fernando DI; Chan MY; Sia CH
    Ann Acad Med Singap; 2020 Dec; 49(12):996-1008. PubMed ID: 33463658
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Obesity Increases the Severity and Mortality of Influenza and COVID-19: A Systematic Review and Meta-Analysis.
    Zhao X; Gang X; He G; Li Z; Lv Y; Han Q; Wang G
    Front Endocrinol (Lausanne); 2020; 11():595109. PubMed ID: 33408692
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Obesity: A potential risk factor for infection and mortality in the current COVID-19 epidemic.
    Jayawardena R; Jeyakumar DT; Misra A; Hills AP; Ranasinghe P
    Diabetes Metab Syndr; 2020; 14(6):2199-2203. PubMed ID: 33395781
    [TBL] [Abstract][Full Text] [Related]  

  • 32. COVID-19 and Cancer Comorbidity: Therapeutic Opportunities and Challenges.
    Pathania AS; Prathipati P; Abdul BA; Chava S; Katta SS; Gupta SC; Gangula PR; Pandey MK; Durden DL; Byrareddy SN; Challagundla KB
    Theranostics; 2021; 11(2):731-753. PubMed ID: 33391502
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Blood glucose levels should be considered as a new vital sign indicative of prognosis during hospitalization.
    Kesavadev J; Misra A; Saboo B; Aravind SR; Hussain A; Czupryniak L; Raz I
    Diabetes Metab Syndr; 2021; 15(1):221-227. PubMed ID: 33450531
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The role of SARS-CoV-2 target ACE2 in cardiovascular diseases.
    Zhu H; Zhang L; Ma Y; Zhai M; Xia L; Liu J; Yu S; Duan W
    J Cell Mol Med; 2021 Feb; 25(3):1342-1349. PubMed ID: 33443816
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Friend or foe? ACE2 inhibitors and GLP-1R agonists in COVID-19 treatment.
    Pang J; Liu M; Ling W; Jin T
    Obes Med; 2021 Mar; 22():100312. PubMed ID: 33426364
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Relationship of socio-demographics, comorbidities, symptoms and healthcare access with early COVID-19 presentation and disease severity.
    Vaughan L; Veruttipong D; Shaw JG; Levy N; Edwards L; Winget M
    BMC Infect Dis; 2021 Jan; 21(1):40. PubMed ID: 33421991
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cardiovascular risk factors and mortality in hospitalized patients with COVID-19: systematic review and meta-analysis of 45 studies and 18,300 patients.
    Silverio A; Di Maio M; Citro R; Esposito L; Iuliano G; Bellino M; Baldi C; De Luca G; Ciccarelli M; Vecchione C; Galasso G
    BMC Cardiovasc Disord; 2021 Jan; 21(1):23. PubMed ID: 33413093
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Hypertension and Electrolyte Disorders in Patients with COVID-19.
    Lim JH; Jung HY; Choi JY; Park SH; Kim CD; Kim YL; Cho JH
    Electrolyte Blood Press; 2020 Dec; 18(2):23-30. PubMed ID: 33408744
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of COVID-19 on Pre-existing Liver disease: What Hepatologist Should Know?
    Sharma P; Kumar A; Anikhindi S; Bansal N; Singla V; Shivam K; Arora A
    J Clin Exp Hepatol; 2021; 11(4):484-493. PubMed ID: 33398223
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Cardiovascular diseases and COVID-19 : Pathophysiology, complications and treatment].
    Schieffer E; Schieffer B; Hilfiker-Kleiner D
    Herz; 2021 Mar; 46(2):107-114. PubMed ID: 33394058
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.